ACOG - Alpha Cognition Inc.
4.43
-0.400 -9.029%
Share volume: 59,078
Last Updated: 04-07-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
-0.02%
PREVIOUS CLOSE
CHG
CHG%
$4.83
-0.40
-0.08%
Fundamental analysis
0%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
0%
Performance
5 Days
-11.22%
1 Month
-19.01%
3 Months
-27.38%
6 Months
-27.38%
1 Year
-27.38%
2 Year
-27.38%
Key data
Stock price
$4.43
DAY RANGE
$4.36 - $4.99
52 WEEK RANGE
$4.28 - $6.75
52 WEEK CHANGE
-$27.38
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-20-2025
Company detail
CEO: Michael McFadden
Region: US
Website: www.alphacognition.com
Employees: 0
IPO year: 2021
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
Region: US
Website: www.alphacognition.com
Employees: 0
IPO year: 2021
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
The Company is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease, for which there are limited or no treatment options. Alpha Cognition Canada Inc. became the Company’s wholly-owned subsidiary. Our principal executive offices are located at 1200 – 750 West Pender Street, Vancouver, British Columbia. Our offices in the United States are located at 20073 Fiddler’s Green, Frisco, Texas.
Recent news
